Monash IVF Group books revenue of $269.5M in FY26
- Monash IVF recorded FY26 revenue of $269.5 million and underlying net profit after tax of $16.1 million.
- Results fell below updated June guidance due to lower domestic volume and cost inflation.
- Domestic market share grew to 20.2% in the second half alongside ongoing productivity initiatives.
Monash IVF Group (ASX:MVF) reported FY26 revenue of $269.5 million alongside an underlying net profit after tax of $16.1 million.
The underlying net profit missed the company's June guidance range of $17 million to $18 million following domestic cycle volume pressures.
"While the first half was challenging, we exited the year with improving momentum, with domestic stimulated cycle volume trends strengthening, market share increasing through the second half and our international businesses delivering record performance," said said Monash IVF Group CEO and Managing Director, Dr Victoria Atkinson.
Revenue dipped 0.9% compared to FY25, while underlying EBITDA fell 19.5% due to wage inflation and fixed clinical operating costs.
The earnings figure included a $1.4 million post-tax write-off of prepaid assets alongside higher supplier costs.
Market share in domestic stimulated cycles improved to 20.2% in the second half as clinical pregnancy rates strengthened.
Following the announcement, the Monash IVF Group share price was down at $0.68.
The group completed strategic capital investments during the year, including a new Brisbane fertility clinic and day hospital facility.
Centralised procurement and workforce efficiency programmes are expected by the company to enhance operating leverage moving forward.
